Diffuse Lewy body disease is a common neuropathological condition which is associated with clinical features of parkinsonian dementia.'2 At least 20% of all patients with Parkinson's disease develop dementia.3 Conversely at least 30% of patients with dementia develop signs of parkinsonism.4" The pathological basis of these parkinsonian dementia syndromes is poorly understood. The dementia has in the past generally been attributed to the pathological changes of Alzheimer's disease but recent clinicopathological studies have provided little or no support for this explanation, finding either no evidence of Alzheimer's disease'2 '3 or only sparse changes'4 1" which fail to meet diagnostic criteria for Alzheimer's disease'6 17 and do not correlate with the severity of the dementia.'8 Diffuse Lewy body disease provides an alternative explanation.
Diffuse Lewy body disease is characterised by the presence of eosinophilic hyaline inclusion bodies (that is, Lewy bodies) in both subcortical and cortical areas. 1123 The brainstem Lewy bodies closely resemble those seen in Parkinson's disease both in morphology Difuse Lewy body disease: correlative neuropathology using anti-ubiquitin immunocytochemistry The brains (or randomly selected half-brains in the eleven cases where the brain had been bisected sagittally in the fresh state and one half frozen for neurochemistry) were fixed in 10% formol saline for at least six weeks and then dissected in a standardised fashion. The cerebral cortex was divided into one centimetre coronal slices and blocks were taken from the major neocortical regions and from entorhinal cortex, periamygdaloid cortex and hippocampus; insular cortex and basal nucleus of Meynert at the level of the midpoint of the anterior commissure; and anterior cingulate gyrus from the same slice. The brainstem was sliced transversely at the level of the oculomotor nerve to obtain a substantia nigra block; longitudinally through pons for locus ceruleus; and transversely through medulla for dorsal vagal nucleus. These blocks were processed in paraffin wax and sectioned at 10 micrometres.
The sections were stained using H and E, cresyl-fast violet, solochrome-cyanin, thioflavine S, the Cross modification of Palmgren's silver stain3" and anti-ubiquitin immunocytochemistry.' Anti-ubiquitin immunocytochemistry was performed using a rabbit polyclonal antibody which showed high specificity for ubiquitin-protein conjugates in vitro and in tissue sections as previously described,2336 with a streptavidin-biotin-peroxidase detection system. 37 All neuropathological assessments were carried out on core were counted; less clearly defined forms of senile plaque laboratory-coded slides without knowledge of the patient's (so-called primitive or early plaques) were excluded. identity or clinical details.
In all cases Lewy body density was also assessed using conventional H and--E stins of adjacent sections. The Assessment ofdementia severity densities obtained by this method were proportional to those All of these cases had spent time-under the care of the obtained using anti-ubiquitin immunocytochemistry but Department of Health Care of the Elderly and had underinvariably lower, reflecting the difficulty in identifying gone detailed assessment of cognitive function. There was a highly significant correlation between dementia severity and cortical Lewy body density in each of these cortical regions (p < 0-001) (figure 4 a-d). They were less abundant in Lennox, Lowe, Landon, Byrne, Mayer, Godwin-Austen superior frontal and superior parietal lobes, but here too there was a significant correlation between cortical Lewy body density and dementia severity (p < 0 005) (figure 4 e-f). A highly significant correlation was also found between the mean cortical Lewy body density in all six cortical regions and dementia severity (p < 0.001) (figure 5). Lewy bodies were rare in the hippocampus (and occurred almost exclusively in the subiculum: no Lewy bodies were identified in the dentate gyrus), but again there was a significant correlation between subiculum Lewy body density and dementia severity ( (table 1) . This study confirms previous reports that there is also considerable pathological overlap. In particular the brainstem pathology of the two diseases is for practical purposes indistinguishable, with both showing cell loss, gliosis and classical Lewy body formation in the substantia nigra, locus ceruleus and other brainstem nuclei. The only difference identified by this study is that a greater proportion of the remaining substantia nigra neurons contain Lewy bodies in diffuse Lewy body disease, raising the possibility that there is an increased tendency to Lewy body formation in this disease.
There is also pathological overlap in the nucleus basalis of Meynert, as discussed above. The striking difference between non-demented Parkinson's disease and diffuse Lewy body disease lies in the numbers of cortical Lewy bodies. No cortical Lewy body was detected in four of the seven cases of non-demented Parkinson's disease despite an extensive search using anti-ubiquitin immunocytochemistry. In the remaining three cases Lewy bodies were not detected using routine H and E stains but anti-ubiquitin immunocytochemistry revealed small numbers, for example, between 1 and 3 Lewy bodies in the insular cortex (that is, 0-01-004 Lewy bodies/mm2) and either 0 or 1 Lewy body in entorhinal cortex (that is, 0-006 Lewy bodies/ mm2) (table 2). Far larger numbers (and greater densities) of Lewy bodies were detected in each of the cases of diffuse Lewy body disease. The small number of cortical Lewy bodies found in non-demented cases ofParkinson's disease is consistent with the hypothesis that dementia is related to cortical Lewy body density with symptoms of cognitive impairment developing only when a certain threshold has been exceeded. This "spectrum hypothesis" was first proposed by Yoshimura et alP 4 who classified cases of Lewy body disease into three groups, from Group C who had classical Parkinson's disease without dementia and brainstem but not cortical Lewy bodies, through to Group A (which they termed diffuse Lewy body disease) who were demented and had large numbers of cortical Lewy bodies as well as brainstem Lewy bodies. Between these groups lay Group B termed "transitional Lewy body disease", which had brainstem Lewy bodies but fewer cortical Lewy bodies and a lower incidence of dementia. If one accepts this hypothesis (without necessarily accepting its nomenclature), it follows that diffuse Lewy body disease can only be distinguished pathologically from Parkinson's disease by applying essentially arbitrary diagnostic criteria based on quantitative estimates of cortical Lewy body density. It would seem reasonable to select the density at which symptoms of dementia first appear, but this point is difficult to define clinically and is in any case poorly represented in this series. On the basis of the present series it is possible to propose provisional criteria which have the advantage of practical simplicity. For example, in the anterior cingulate gyrus (which is small, easy to scan and invariably affected in cases of diffuse Lewy body disease in our experience) the presence ofmore than 12 cortical Lewy bodies in an anti-ubiquitin immunocytochemistry preparation or more than five on an H and E preparation would include all the moderate to very severely demented cases (that is, those demented by conventional criteria65), but exclude the nondemented Parkinson's disease cases. It must, however, be emphasised that such definitions are tentative and arbitrary. Until larger studies of non-demented PD patients and mildly affected cases of diffuse Lewy body disease are available, it might be prudent to retain the spectrum hypothesis and quantify cortical Lewy body density thoroughly in individual cases.
From this study, however, we can conclude that diffuse Lewy body disease is a common substrate of parkinsonian dementia and that the dementia is related to a cortical process which involves Lewy body and senile plaque formation. Further understanding is likely to develop rapidly, as awareness ofthe condition increases: in particular clinicians should consider diffuse Lewy body disease in the differential diagnosis of cases of parkinsonian dementia and neuropathologists should seek cortical Lewy bodies with a sensitive technique such as anti-ubiquitin immunocytochemistry.
